US/UK/Canada

Share

Links

Quotes

First of all, it is an honor to be recognized by ESMO, and we are thrilled to exhibit our promising results for OT-1096 for the first time. Even more so, being part of changing the treatment landscape for cancer at this time is exciting for us: the 2018 Nobel Prize in Medicine was awarded for pioneering work in immunooncology and we see more and more traction and exciting results from novel immunomodulatory small molecules, such as ours, with the capacity to favorably change the immune system inside tumors.
Prof. Owe Orwar, CEO at Oblique Therapeutics.
Pick a time period -
Tags ( Active)

Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage

Stockholm, Sweden – October 22, 2024 – Oblique Therapeutics AB (“Oblique”) announces that the company's research project on the NaV1.8 ion channel has reached an important milestone. After successfully completing the first stage of the project, where the Company’s AbiProt technology is used to identify potential binding sites for therapeutic antibodies on the target protein, the project is now in the process of developing antibodies against NaV1.8.The ion chanel Nav 1.8 is a well established target of high importance in pain. In May, the company started a campaign to identify potential

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt[®] technology to generate antibodies to a high-value target

Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt[®] technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties. Under this collaboration agreement, Oblique will partner with Lilly Catalyze360-ExploR&D, a

Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers.

Stockholm, Sweden - 10 June 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures. This partnership aims to accelerate research and development in the area of innovative treatments for various illnesses. The PDC Center for High Performance Computing (PDC) at KTH hosts the most powerful supercomputer within the National

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD . as Chief Executive Officer.

Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1[st] December 2022.Christer Nordstedt has abroad and extensive international experience within the pharmaceutical industry from operational and strategic positions at management level in companies like Vivesto, Teva Pharmaceuticals, Orion Corporation, Eli Lilly,

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Press release – New Patent granted Gothenburg, Sweden, 14 January 2022 – Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and developing pharmacologically tailored antibodies against clinically important targets has been granted by the USPTO as US Patent No. 11,161,901 B2. The technology uses artificially intelligent molecular probes and mass spectrometry to identify antibody binding sites on clinically relevant targets, many of which have been considered undruggable with antibodies. The AbiProt® proteomics technology from Oblique

Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals

Press Release Gothenburg, Sweden,  15 November 2021 – Oblique Therapeutics, a biotech company focused on new antibody medicines for severe diseases with large unmet medical needs, is delighted to introduce newcomers in charge of Investors Relations Management and Business Development activities to reinforce it commercial activitiesOblique Therapeutics welcomes Cecilia Larsson who has joined the business team as IRM-Investors Relations Manager at the Gothenburg Office. Cecilia has extensive business relationship customer experience, and will be a great addition to Oblique’s business team.

Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.

Press release 14 October, 2021 Gothenburg, 14 October 2021 – Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, will present the recent progress on its anti-Thioredoxin mAb program at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, Nov 10 -14, Washington DC, USA.The poster titled ” Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody ” will describe the identification of high affinity monoclonal antibodies against human Thioredoxin and in vitro and in

Oblique Therapeutics announces achievement of key milestone in its aKRAS-mAb program and Abiprot® platform

Press Release , 27 September, 2021  Gothenburg, Sweden, 27 Sept 2021 - Oblique Therapeutics today announces that it has reached a key milestone in its aKRAS antibody program and achieved validation of its Abiprot® platformOblique Therapeutics has developed a unique, proprietary methodology Abiprot[®] to identify epitopes on targets that have previously proven difficult to address with antibodies. Using this platform, a few epitopes were identified in KRAS, one of which encompassed the frequently mutated amino acids 12 and 13. Interestingly, this epitope is not well exposed in any of

Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas

Press Release April  19th,  2021 Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas Gothenburg, Sweden, April  19th, 2021 – Oblique Therapeutics AB,  a Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results in the highly-acclaimed scientific journal Science Advances (AAAS) entitled: Rational Antibody design for

Oblique Therapeutics AB, raises 98 MSEK in a private placement investment round.

Press Release November 18, 2020 Oblique Therapeutics AB, raises 98 MSEK in a private placement investment round. Gothenburg, Sweden, November 18, 2020  Oblique Therapeutics AB, a privately held Swedish biotech company, announces today that it has received 98 MSEK from new investors and shareholders including several Swedish institutional investors and European venture capital investment firm Sunstone Life Science Ventures after a successful fundraising campaign led by Västra Hamnen Corporate Finance AB.The financing will enable Oblique Therapeutics AB to further accelerate its

Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova.

Press Release, October 8, 2020 Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot[TM] platform into a first-line-of-defence for future pandemics.Gothenburg, Sweden, October 8, 2020  Using the proprietary Abiprot[TM] antibody discovery platform, Oblique Therapeutics and collaborators had earlier this year demonstrated that potential epitopes for neutralizing antibodies can be identified

Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

Press Release June 29,2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms  · Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot[TM] technology platforms · ONCOS will be used to deliver Abiprot[TM] antibodies against hard-to-reach targets such as mutant RASGothenburg, Sweden & Oslo, Norway,June 29 2020 – Oblique Therapeutics today announces that it has entered into a collaboration agreement with Targovax ASA (OSE: TRVX)

Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies

Press Release June 11, 2020   Gothenburg, Sweden, June 11, 2020 - Using the Abiprot[TM] antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients. The epitope is part of the spike protein which mediates the virus entry into cells. It was identified in a pilot study using virus material from the nasal swab of a Covid-19 patient.This early proof-of-concept result is very encouraging and has prompted Oblique Therapeutics and their collaborators to

Oblique Therapeutics will be presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020

Gothenburg, Sweden, October 24, 2019 – Oblique Therapeutics AB announces that Sreesha P Srinivasa is on the list of invited speakers who will be presenting at the RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020.Sreesha P Srinivasa, Senior Vice President at Oblique Therapeutics will be presenting the company’s KRAS antibody program, targeting KRAS driven malignancies such as lung and colon cancer, at the summit early next year. The summit unites experts in the RAS field; big pharma, biotech and academia. They are all trying to develop medicines targeting RAS, a

Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine

Gothenburg, Sweden, July 17, 2019 – Oblique Therapeutics, a Swedish biotech focusing on generating novel therapeutic antibodies towards severe diseases such as cancer and pain, has been honored as one of the most promising biotech startup in Europe 2019 by StartUp City magazine. An interview with the CEO, Owe Orwar is featured on the cover story of the BioTech special issue published this month.StartUp City Magazine: “Oblique Therapeutics is uncovering medical breakthroughs in antibody therapeutics using its proporietary technology platform AbiprotTM ”. The AbiprotTM technology enables the

Oblique Therapeutics present tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO

Gothenburg, 09 Oct 2018 – Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, today announced that it will present new promising preclinical data for the drug candidate OT-1096 in triple-negative breast cancer (TNBC) at the largest oncology congress in Europe, the European Society for Medical Oncology (ESMO), held 19-23 October in Munich, Germany.The new data of the first-in-class anti-cancer agent OT-1096 shows promising preliminary results with improved tumor growth inhibition compared to pembrolizumab, one of the blockbuster drugs

Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer

The Gothenburg, Sweden based biotech company Oblique Therapeutics AB today announced that the world-leading medical journal Science Translational Medicine in its latest issue has published promising preclinical research results on a new type of molecules against advanced cancer. The results are based on a collaboration with Professor Elias Arnér's research group at Karolinska Institute in Stockholm. In the article, titled Irreversible Inhibition of Cytosolic Thioredoxin Reductase 1 as a Mechanistic Basis for Anticancer Therapy, the researchers show that tumor growth is effectively

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe